Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
This page provides an archive of news and press releases related to Centogene N.V. (historically associated with the symbol CNTG). The company has described itself as the essential life science partner for data-driven answers in rare and neurodegenerative diseases, integrating multiomic technologies with the CENTOGENE Biodatabank to support diagnosis and pharmaceutical research.
News items for Centogene cover several themes. These include announcements about large-scale research initiatives such as the Rostock International Parkinson's Disease (ROPAD) Study, which focuses on the genetics of Parkinson’s disease and has generated findings on genetic risk factors and the prevalence of specific variants. Releases also describe collaborations in lysosomal diseases and Gaucher disease, including work with partners like Critical Path Institute and Evotec SE, where CENTOGENE’s data and biomarkers have been used alongside external platforms to identify and characterize potential therapeutic candidates.
Other historical news highlights corporate and financial developments, such as strategic collaborations, joint ventures, financing arrangements, and the company’s strategic alternatives review. A key set of announcements in late 2024 and early 2025 detail the agreement and subsequent closing of the sale of Centogene N.V.’s operating subsidiaries to an affiliate of Charme Capital Partners, shareholder approvals at an Extraordinary General Meeting, and the company’s stated intention to enter dissolution and liquidation following the transaction.
Because Centogene N.V. has reported that, after the sale of its operating subsidiaries, it and its remaining subsidiary will no longer have operations and will enter dissolution and liquidation, the CNTG news flow is best understood as a historical record. Investors and researchers can use this page to review how the company described its multiomic diagnostics, Biodatabank, research collaborations, and the sequence of corporate events leading up to the sale of its operating subsidiaries and planned liquidation.
CENTOGENE and Evotec announced the discovery of a promising new molecule with potential to treat type 2 and type 3 Gaucher disease. The discovery stems from their ongoing drug discovery partnership initiated in 2020, now extended for another year. Evotec has received an R&D license for continued development and has an exclusive option until March 31, 2025, to license CENTOGENE’s share of the IP. If exercised, CENTOGENE will receive an upfront fee, milestone payments, and royalties. Preclinical studies show the molecule has high brain penetration and metabolic stability, indicating significant progress towards a treatment for neuronopathic Gaucher disease.
CENTOGENE N.V. (Nasdaq: CNTG) announced significant growth in the CENTOGENE Biodatabank, with over 850,000 diverse patient insights for rare and neurodegenerative diseases. The data aids in precise diagnosis, new genetic variant identification, and drug development de-risking. With patients from 120+ countries, the biobank supports a vast diagnostic testing portfolio, 300 publications, and 48 pharma collaborations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.